Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

Key Inclusion Criteria:

1. Skin of color, defined as Fitzpatrick skin type ≥4 at screening visit

2. Diagnosis of moderate-to-severe atopic dermatitis (AD) that cannot be adequatelycontrolled with topical AD medications, as defined in protocol

3. Has applied a stable dose of topical emollient (moisturizer) twice daily as perphysician recommendation starting at screening visit

Key Exclusion Criteria:

1. Self-reported Caucasian or White race

2. Adolescent body weight less than 30 kg at screening

3. Prior use of dupilumab within 6 months of screening

4. Concomitant skin diseases or other pigmentary disorder that could confound ADassessments

5. Current or prior use, within 12 weeks before the screening visit, of phototherapy ortanning beds

6. Active helminthic infections; suspected or high risk of helminthic infection, unlessclinical and (if necessary) laboratory assessments have ruled out active infectionbefore baseline

7. Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI)within 7 days prior to baseline

8. Planned or anticipated use of any prohibited medications and procedures, as definedin protocol

9. Has received a COVID-19 vaccination within 1 week of planned start of studymedication or for which the planned COVID-19 vaccinations would not be completed 1week prior to start of study drug

NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply